Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
3,825 people get SRPT articles and Market Currents by email alert.
Get email alerts on SRPT »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
Marketwire (May 10, 2013)
-
-
-
-
-
-
-
-
-
Marketwire (Apr 18, 2013)
-
-
-
-
AVI BioPharma, Inc. Q2 2008 Earnings Call TranscriptMon, Aug 11, 2008
-
AVI BioPharma, Inc.Q4 2007 Earnings Call TranscriptWed, Mar 12, 2008
-
AVI Biopharma Q3 2005 Earnings Conference Call Transcript (AVII)Fri, Nov 4, 2005
-
Marketwire (May 10, 2013)
-
Marketwire (Apr 18, 2013)
-
at MarketWatch.com (Apr 16, 2013)
-
at CNBC.com (Apr 15, 2013)
-
at CNBC.com (Apr 3, 2013)
-
at CNBC.com (Apr 2, 2013)
-
at CNBC.com (Mar 19, 2013)
-
at Fox Business (Feb 20, 2013)
-
at CNBC.com (Feb 20, 2013)
-
at CNBC.com (Jan 29, 2013)
-
at MarketWatch.com (Nov 27, 2012)
-
at CNBC.com (Nov 21, 2012)
-
at MarketWatch.com (Nov 13, 2012)
-
at MarketWatch.com (Nov 6, 2012)
SRPT vs. ETF Alternatives
Company Description
Sarepta Therapeutics – formerly AVI BioPharma – is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company’s diverse pipeline includes its lead program eteplirsen, for... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 9, 8:27 AM More on Sarepta Therapeutics' (SRPT) Q1: Nothing particularly groundbreaking regarding eteplirsen in the PR. The company says it is "encouraged" by its correspondence with the FDA and is "finalizing" its response to requests for further information (I, II). A $6.7M decrease in government contract revenue is blamed for the higher (Y/Y) operating loss. Operating expenses were higher as the company expands its Duchenne muscular dystrophy program. Shares +1.24% premarket. 2 Comments [Earnings, On the Move, Healthcare]
- Thursday, May 9, 7:01 AM Sarepta Therapeutics (SRPT): Q1 EPS of -$0.41 beats by $0.21. Revenue of $4.5M misses by $1.35M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, May 9, 12:05 AM Notable earnings before Thursday’s open: AES, AGU, ALR, AM, AMRC, APA, BAM, BCE, CBB, CNSL, CTB, CVC, DF, DISH, DNDN, GLP, GTIV, IRC, KEM, KIOR, MEA, NPSP, OWW, PCP, SNE, SNSS, SPH, SRPT, TK, TNK, VICL, VNDA, WAC, WFR, WIN, WWAV, XRAY Comment! [Earnings]
- Wednesday, May 8, 5:30 PM Notable earnings before Thursday’s open: AES, AGU, ALR, AM, AMRC, APA, BAM, BCE, CBB, CNSL, CTB, CVC, DF, DISH, DNDN, GLP, GTIV, IRC, KEM, KIOR, MEA, NPSP, OWW, PCP, SNE, SNSS, SPH, SRPT, TK, TNK, VICL, VNDA, WAC, WFR, WIN, WWAV, XRAY Comment! [Earnings]
- Wednesday, April 24, 12:42 PM The latest chatter on Sarepta's (SRPT -3.7%) etiplirsen: Edison Investment Research's Jason Zhang notes that the FDA is now "squarely in the middle of the bull and bear scenarios" for SRPT and says the regulator will make a decision on the company's NDA application for etiplirsen "likely before the end of the year." By contrast, Leerink Swann said last week the company may "need to run a Phase III trial in 2014." 2 Comments [Healthcare, On the Move]
- Monday, April 22, 8:28 AM Sarepta Therapeutics (SRPT) gets a 3% premarket lift from an initiation at Needham (Buy). Analyst Chad Messer is positive on eteplirsen and says he believes "the market reacted inappropriately to last week's regulatory update." The FDA requested "additional information" last Monday in order to evaluate an Accelerated Approval application, news the market did not like. (See also: Leerink Swann uncertain about SRPT) 1 Comment [On the Move, Healthcare]
-
Tuesday, April 16, 12:59 PM
Midday top 10 gainers: UNXL +16%. CNIT +15%. ANEN +15%. CHCI +14%. SYNM +13%. PNFP +12%. EVC +12%. ENPH +11%. NCQ +11%. ACOR +11%.
Midday top 10 losers: JAXB -33%. KEYN -15%. SRPT -12%. CPGI -10%. GENE -10%. TRIT -9%. CCXI -9%. MAGS -9%. ADAT -8%. GAI -8%. Comment! [On the Move] -
Tuesday, April 16, 9:10 AM
Premarket gainers: NWBO +9%. GFI +7%. BCRX +7%. HK +7%. AU +7%. NG +6%. AUQ +6%. SAND +6%. GOLD +5%. KGC +5%.
Losers: LDK -16%. SRPT -11%. 1 Comment [On the Move] - Tuesday, April 16, 9:03 AM A downgrade from Leerink Swann to Market Perform from Outperform adds to Sarepta Therapeutics' (SRPT) problems. The FDA's request has "prolonged uncertainty" and the need to run a Phase III trial preapproval could give GlaxoSmithKline (GSK) and Prosensa's drisapersen treatment a first-to-market advantage. SRPT shares now -10.17% premarket. 2 Comments [Healthcare, On the Move]
- Tuesday, April 16, 8:17 AM Investors appear skeptical about the FDA's request for additional information from Sarepta Therapeutics (SRPT) regarding the company's Duchenne muscular dystrophy drug. CEO Chris Garabedian says he does not anticipate "an impact on SRPT's ongoing activities" from the FDA's request or from the delay it occasioned in the accelerated approval submission process. Nonetheless, the shares are -6.22% premarket. Comment! [Healthcare, On the Move]
-
Monday, April 15, 5:47 PM
After-hours top gainers, as of 5:15 p.m.: CNW +6%. SPR +6%. SWC +5%. RES +4.5%. RBC +4.4%.
After-hours top losers: SRPT -12%. CLI -7%. HCA -5%. EGOV -4.0%. KDN -3.2%. Comment! [On the Move] - Monday, April 15, 4:22 PM Sarepta Therapeutics (SRPT) says the FDA is considering accelerated approval of eteplirsen for the treatment of Duchenne muscular dystrophy. The agency has requested SRPT provide additional information from its existing dataset to help facilitate a decision on its acceptability for a New Drug Application filing under the Subpart H Accelerated Approval regulatory pathway. Shares -0.4% AH. 1 Comment [Healthcare, On the Move]
- Monday, April 15, 3:59 PM A brief move into positive territory by Sarepta Therapeutics (SRPT -2.7%) midday might have been the result of comments from Wedbush (Outperform) analyst Christopher Marai who says progress on FDA approval for the company's Duchenne muscular dystrophy drug Eteplirsen is "encouraging." 2 Comments [Healthcare]
- Sunday, April 14, 8:25 AM The reconstitution of the Russell indexes coming up in June, Credit Suisse aims to anticipate who's in and who's out. The rules-based approach of the Russell 2000 has allowed arbitragers to profit each summer by front-running the moves, making the Russell 2000 ETF (IWM) a poorer play for small cap fans than IJR . Expected among the top 25 adds are ARCP, SRPT, PBYI, ACAD, and WSTC. Among the top 25 deletes: CPST, FCEL, CHKE, OMER, and EML. Comment! [Quick Ideas]
- Friday, April 5, 2:22 PM Piper Jaffray weighs in on Sarepta's (SRPT +5.3%) earlier data update on its Phase IIb study of on eteplirsen saying its very encouraged as there are no treatment options for DMD. The primary near-term value driver in the stock is SRPT's decision to file for accelerated approval later this month. Piper projects a 50/50 chance it will be able to file on existing data. Comment! [Healthcare, On the Move]
- Friday, April 5, 11:02 AM Sarepta Therapeutics (SRPT +5.5%) racks up solid gains today after the therapeutic drug developer announced positive updated data from its Phase IIb study of eteplirsen in patients with Duchenne muscular dystrophy. Results at 74 weeks showed a continued stabilization of walking ability in eteplirsen-treated patients on a 6-minute walk test. Comment! [Healthcare, On the Move]
-
- View all 0 replies
-
The Wall Street Transcript
Sarepta Therapeutics ($SRPT) Muscular Dystrophy Franchise Significantly Undervalued- http://su.pr/7uhCh2 - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Ryan Mallory
LiveCharts: Markets, Stocks & Watchlists | Some trade ideas in $VLO $DISCK $TDW $SRPT $WDAY http://bit.ly/XohYhB - View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
Brad Kenagy
BillMauer $KERX 24.26%,MattSchilling $IMUC 21.43%,Isreal Shenker $KNDI 6.99%,EWBarnaba $ZTS 4.92%,mktlab68 $SRPT 4.33% http://bit.ly/TrJs0h - View all 2 replies
-
-
Brad Kenagy: It's a contest I am running to see who can provide Alpha by posting a positive return,and beat the $SPY.The link has the contest details.
-
- View all 1 replies
-
-
- View all 3 replies
-
R.S. Analytics: I currently own the stock but if I didn't I would be a buyer in the 20's.
-
-
R.S. Analytics
$ARNA $AVNR $AMRN $SRPT....new article: http://tinyurl.com/bz64k3v Lots of trading opportunities coming up!!! - View all 3 replies
-
R.S. Analytics: Good call - I would wait till around $26 to position in. If they release steller 60wk data, with a low float, this could easily hit $75.
-
-
Scott Matusow
From yesterday: $ZGNX chart and $SRPT: Did I get it right? find out at http://bit.ly/Qss4GL - View all 8 replies
-
Scott Matusow: Thanks Guys! and good to hear Droney, glad I can help offer ideas to people. Thank Seeking Alpha as well for allowing so many diverse ideas.
-
-
smokeyRose
Should i sell Should i sell My $JAZZ and $NPSP and Buy $SRPT ????? What to do What To Do What To Do - View all 2 replies
-
-
-
- View all 3 replies
-
-
-
- View all 1 replies
-
Noreika: Damn. Congrats to all those who bought before mid-summer. Wowsers!!!
-
- View all 12 replies
-
drpharm: its legitimate, i have to wait until tomorrow, buts its okay, im on the upside overall because of your picks. its just a flesh wound haha
-
-
- View all 6 replies
-
Maria Auziliadora: has traded over 12 million shares some people re going to lose big
-
-
- View all 2 replies
-
-
iadops40: Lazard Capital said with maximum U.S. revenue shares of SRPT could be worth $83-$139/share http://bit.ly/PyspFu
-
Michael Bryant
I have to agree with Cramer, Sarepta Therapeutics' (SRPT) orphan drug status could be a huge advantage. http://bit.lyPxXDwC__source=yahoo|headline|quote|video|&par=yahoo - View all 5 replies
-
Michael Bryant: Truffel: Yup, few patients, but you get federal help and a lot of exclusivity.
-
-
- View all 6 replies
-
tomfalbo: that was a great ride - 125%. Cant wait to see how it plays out over the next month.
-
-
- View all 4 replies
-
R.S. Analytics: If the 48 week data is positive for eteplirsen I think SRPT will easily hit $20+. Small float, large short interest, accelerated approval.
-
-
The Scientist
SRPT 50:50 chance of FDA approval without P3. Huge unmet medical need vs. extremely small P2 study. - View all 1 replies
-
EquiMan: Upside ridiculous if you are right. 10-15 more patients would have helped.